| Literature DB >> 26871899 |
Patrick Kaszubski1, Tal Ben Ami, Celine Saade, R Theodore Smith.
Abstract
Geographic atrophy (GA) and choroidal neovascularization (CNV), the two late forms of age-related macular degeneration, are generally considered two distinct entities. However, GA and CNV can occur simultaneously in the same eye, with GA usually occurring first. The prevalence of this combined entity is higher in histological studies than in clinical studies. No distinct systemic or genetic risk characteristics are associated with the combined GA/CNV entity, although on clinical examination and retinal imaging it can feature drusen or subretinal drusenoid deposits. GA and CNV may exist within the spectrum of a single disease, or they may be two very different diseases. Therapy with antivascular endothelial growth factor (anti-VEGF) is often successful for CNV, but some evidence suggests increased rates of GA development in eyes treated with anti-VEGF. In this article, we review the current literature regarding the epidemiology, clinical presentation, and treatment options for patients with the combined GA/CNV entity.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26871899 PMCID: PMC4845740 DOI: 10.1159/000443209
Source DB: PubMed Journal: Ophthalmic Res ISSN: 0030-3747 Impact factor: 2.892